Contents

Research Reports

Resource allocation to brain research in Europe (RABRE)
P. Sobocki, I. Lekander, S. Berwick, J. Olesen and B. Jönsson

Calcium-calmodulin-dependent protein kinase II phosphorylation modulates PSD-95 binding to NMDA receptors
F. Gardini, F. Polli, F. Cattabeni and M. Di Luca

Nipple, a novel hept-loop-hept PAS domain protein, is regulated in response to cerebral ischemia

The cytokine/neurotrophin axis in peripheral axon outgrowth
G. Gölz, L. Uhlmann, D. Lüdecke, N. Markgraf, R. Nitsch and S. Hendrix

Hypothalamic propiomelanocortin (POMC) neurons have a cholinergic phenotype
B. Meister, B. Gömüç, E. Suarez, Y. Ishii, K. Dürr and L. Gillberg

N-ethylmaleimide increases release probability at GABAergic synapses in layer I of the mouse visual cortex
K. Kirmse and S. Kirischuk

Second-by-second measurement of acetylcholine release in prefrontal cortex
J. P. Bruno, C. Gash, B. Martin, A. Zmarowski, F. Pomerleau, J. Burmeister, P. Huettl and G. A. Gerhardt

Repair process of fetal brain after 5-azacytidine-induced damage
M. Ueno, K.-i. Katayama, H. Yamauchi, A. Yasoshima, H. Nakayama and K. Doi

The serotonergic inhibition of slowly bursting cells in the intergeniculate leaflet of the rat
T. Blasik, S. Steija, S. Rissan, P. Pavet and M. H. Lewandrowski

Enamorines and noradrenaline emphysema converge to mechanisms to depress excitatory synaptic transmission in the rat nucleus accumbens in vitro
S. B. Kombian, K. V. V. Ananthakrishni and J. G. Edalighty

Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons
C. Jonghe, P. L. Lemelé, H. Okano, K. Kobayashi and L. E. Trudeau

Topographical organization of pathways from somatosensory cortex through the pontine nuclei to tactile regions of the rat cerebellar hemispheres
T. E. Leergaard, S. Uhlmann, E. D. De Schutter, J. M. Bowser and J. G. Dias

Difference in organization of corticothalamic and thalamostriatal synapses between patch and matrix compartments of rat neostriatum
F. Fujiyama, T. Unzai, K. Nakamura, S. Nomura and T. Kaneko

Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat
P. R. Holand, S. Akerman and P. J. Goodfady

Continued on inside back cover

Cover Illustrations

Map transformations in the rat somatosensory system. Tactile information from the body surface is represented in a somatotopic map in the primary somatosensory cortex (left panel). This essentially 2-D cortical map is transformed into a more complex 3-D map in the pontine nuclei (middle), in which somatotopic relations are largely preserved among axonal terminal fields. In the granule cell layer of the cerebellar hemispheres (right), tactile representations are organized in a more complex and disrupted map, referred to as a fractured map, as here shown in folium crus IIa and the paramedian lobule. Body parts are color coded (red, upper lip; purple, whisker; green, trunk; yellow, forelimb; green, hindlimb). For details see T.B. Leergaard et al. (pp. 2801–2812).
Resource allocation to brain research in Europe – a full report

P. Sobocki,1,2 I. Lekander,2 S. Berwick,2 J. Olesen3 and B. Jönsson4
1Karolinska Institutet, Stockholm, Sweden
2Stockholm Health Economics, Vasagatan 38, SE-111 20 Stockholm, Sweden
3Department of Neurology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
4Stockholm School of Economics, Stockholm, Sweden

Keywords: brain disorders, brain research, cost–benefit, Europe, funding, RABRE

Table of contents

Executive summary 1
Introduction 3
European research funding in general 3
European brain research 3
Materials and methods 4
Study design 4
Data collection 4
Method for estimating the size of investments 5
Method for drawing comparisons with US brain research funding and cancer research funding 6
Comparison with cost of brain disorders 6
Assessment of benefits from brain research 6
Results 7
Total funding of brain research 7
Public funding 7
Industry funding 8
Comparative data 11
Research funding in relation to cost of different brain disorders 12
Benefits from brain research 13
Discussion 17
Main findings 17
Methodological aspects 17
Policy implications 19
Conclusions 20
Acknowledgement 20
Abbreviations 20
References 21
List of contributors 23

Executive summary

Background

Brain diseases are all diseases affecting the brain, spinal cord and peripheral nerves, and they include both neurological and psychiatric diseases. Brain research is all research relating to the nervous system and thus covers the traditional concepts of clinical and basic neuroscience. We have previously assessed the burden of brain diseases in terms of disability-adjusted life years (DALY) and in terms of their economic cost. In Europe, brain diseases account for 35% of the overall disease burden and a conservative estimate of their cost is €386 billion per year. These costs will rise considerably in the coming years due to the ageing European population. One way of curbing this increase and possibly decreasing the cost of brain diseases is to intensify research. More brain research may lead to decreased disease
burden, but is also important in itself as it provides better knowledge about normal brain functions such as emotions, aggression, learning and memory. The aim of the present study was to collect information about spending on brain research in Europe and compare this to the burden and cost of brain diseases, research spending in other disease areas, and similar estimates for the US.

Methods

The present study examined all known sources of funding, including government grants as well as charitable and industry funding.

To estimate public spending on brain research across Europe (by both governments and charities), a survey was conducted of primary sources of research funding. This estimate represents the money spent by European institutions, rather than money invested in those institutions, because the latter may include money from outside Europe, for example research funding from the National Institutes of Health (NIH) in the US. Imputations were made for countries with inadequate response rates.

Industry funding was measured by three different approaches: (i) a worldwide survey of pharmaceutical expenditure by disease area; (ii) consideration of the published cost of developing a new drug as applied to the number of new chemical entities (NCEs) launched in Europe in past decades; and (iii) applying the share of drugs for brain diseases that have entered the market between 1985 and 2004 to total research and development (R&D) expenditure by pharmaceutical companies in Europe over the same period.

Furthermore, we assessed the cost–benefit of investment in brain research using different methods.

Results

Total spending on brain research in Europe in 2005 amounted to approximately €4.1 billion, of which €855 million came from the public sector (21% of total funding). Government funding constituted 78% of total public funding while 22% came from charitable foundations. The European pharmaceutical industry spent approximately €3.3 billion on brain research per year (range: €2.7–3.9 billion), corresponding to 79% of the total funding for brain research in Europe. In contrast, in the US, about €6.1 billion came from public sources (93.5% government and 6.5% charities) and €8.4 billion from industry funding (58% of the total funding).

Public funding for brain research varied between European countries, ranging from €60 000 in Malta to €312 million in the UK. Ireland had the highest level of public spending per inhabitant (€6.73), followed by the UK (€5.2) and Hungary (€2.7). The lowest level was found in Latvia (€0.14 per inhabitant). Hungary, the Netherlands, Norway, Sweden and France also had per capita spending above the European average, which was estimated at €1.2.

Fifty-three per cent of the total research spending could be attributed to specific brain disorders. Psychiatric disorders received one-third of investment in brain research while two-thirds went to neurological disorders. In our previous study on the cost of brain disorders, psychiatric disorders accounted for 67% of the overall cost and neurological disorders for 33%. In the present study we found considerable differences between research spending on brain disorders. Affective disorders received total funding of about €600 million, for example, whereas brain tumour received €70 million and traumatic brain injury (TBI) €12 million.

Public funding of brain research amounted to 0.2% of the cost of brain diseases per year and industry funding to 0.8%. Comparing public research spending to the cost of individual brain diseases, brain tumour received proportionately the most funding, at 0.5% of its cost, while affective disorders and migraine received the least (0.035% and 0.025% of their costs, respectively).

Cancer research in Europe received about €1.5 billion of public funding (50% government and 50% charities) and around €2.5 billion of industry funding. The absolute funding of cancer research is approximately the same as the funding of brain research. However, public funding of brain research is smaller and, more significantly, the cost and burden of brain disease is almost double that of cancer.

Discussion and policy implications

This is the first evaluation of private and public funding of brain research ever to be conducted in Europe. We consider it an important accomplishment to have gathered the necessary information for these purposes. This would hardly have been possible for any single researcher or group of researchers. However, due to the extensive membership network of the European Brain Council (EBC), it was possible to secure cooperation from most countries. The results strongly suggest that funding of brain research must be increased in Europe, particularly public funding.

While these general statements certainly hold true, more precise conclusions must be drawn with care. In total, 71% of the public funding agencies contacted provided adequate responses to the survey, but only 53% of the countries included provided complete data. The imputations made for countries with no or incomplete data are by definition imprecise.

No data from universities were included in the total estimate, although universities make considerable investments, particularly in basic brain research. This was due to lack of data and the risk of double counting. In many cases we encountered difficulties in differentiating between expenditure on brain research and expenditure on other areas, so the imputations may overestimate research funding in some countries. On the other hand, because some organizations may have been omitted, and because we excluded universities, the results could represent an underestimate. Our best (but still highly uncertain) estimate of university-funded brain research is €700–800 million. Even after inclusion of this figure, public funding of brain research remains low compared to the US, and public brain research funding still constitutes only a minute fraction of the cost of brain disorders. Hence, the aforementioned caveats do not alter the overall conclusions.

Industry funding includes development costs as well as research costs. Our figures for industry funding of brain research may therefore be considered by some to be too high. However, both basic and clinical research is needed to bring new medicines to market and to provide the necessary information for their optimal use. In comparison to the US, there seems to be an under-funding of both basic and clinical brain research in the public sector in Europe. We have not been able to document the interaction between publicly and privately funded research, but this is a key factor for success in bringing new therapies to patients.

Several different analyses showed that increasing brain research would bring great benefits. Even using very conservative estimates, a high financial return on increased investment in brain research was predicted. This was true even within a 10-year period, although the benefits of increasing investment in brain research could endure long into the future, providing substantial annual returns. Our findings are in agreement with previous findings for the US.
Conclusions and recommendations

Spending on brain research in Europe, particularly public spending, is low compared to spending on other fields of research such as cancer, and it is particularly low compared to spending on brain research in the US. Increased public investment in brain research in Europe could be highly cost-effective and bring great benefits. The EC’s prioritization of brain research in the Seventh Framework Programme is supported by the present data. Each European nation should follow the example of the European Commission (EC) and make the brain one of its research priorities for the years to come. It is important that both basic and clinical research receive adequate funding. Basic research is responsible for the most fundamental breakthroughs and often leads to subsequent paradigm shifts in drug development and patient treatment. Clinical research can direct basic research towards disease-related mechanisms and is instrumental in translating basic research findings into new products and treatments.

Using the same methodologies as in the present study, further studies should be undertaken in each European country to more precisely assess spending on brain research. To facilitate such studies, industry and public funding bodies should group funding for ‘brain research’ together, including research on stroke, brain tumour, developmental disorders, mental retardation, brain trauma and brain infections. This in turn would enable policymakers to prioritize investment in brain research in the most appropriate way.

Introduction

European research funding in general

Europe has a long tradition as a leader in R&D. Lately, however, it has been falling behind other major economies (Fig. 1). To strengthen R&D in Europe and bring it in line with other major economies, members of the European Union (EU) agreed to the Lisbon Strategy in 2000, which set out several R&D goals for 2010 (Eurostat, 2005b). Today, over halfway through the timeframe of the Lisbon Strategy, Europe is still far behind the US and Japan, in terms of both R&D intensity [i.e. R&D as a percentage of gross domestic product (GDP)] and number of agencies contributing to R&D investment (Eurostat, 2005b). China is also coming up fast from behind, with R&D expenditures of 1.3% of GDP in 2004.

In 2004, industry accounted for just over half of all R&D funding in Europe (54%). This is substantially lower than in both the US and Japan, where the industry contribution is two-thirds and three-quarters, respectively (Eurostat, 2005b). The Lisbon Strategy goal for R&D intensity was set at 3% of GDP, and the share of industry contribution at two-thirds of total investments (Eurostat, 2005b). Europe has an average R&D intensity below 2% today. This relationship between European and international R&D investments also holds true, in general, for biomedical research and, specifically, research productivity (Philippson, 2005). However, the EU and Switzerland still show a specialization in pharmaceuticals and biotechnology, the sector which showed the fastest growth in R&D spending in 2001–2004 ([European Federation of Pharmaceutical Industries and Associations (EFPIA), 2006].

European brain research

Europe led in brain research until 10–20 years ago (Murphy & Topel, 2003). For the past decade, however, the US has been and continues to be the leading region in terms of brain research funding. The gap between European and American brain research is widening (Murphy & Topel, 2003). If Europe is to be a competitive region in brain research, this trend must be reversed. More information is therefore needed on resource allocation to brain research in Europe and on the potential benefits to be gained from increasing the funding of brain research.

The ‘Cost of Disorders of the Brain’ study (Andlin-Sobocki et al., 2005) evaluated the cost of brain disorders in Europe and is a starting point for understanding the economic impact of brain disorders on European society. The study focused on the cost of the 12 most prevalent brain disorders [for definitions see appendix to the present study at http://www.europeanbraincouncil.org/publications] and included mental, neurological and neurosurgical disorders. It estimated all costs to society, including healthcare costs (hospital care, ambulatory care and drugs), private and public costs outside the medical sector (nursing home costs and services and goods for private homes) as well as indirect costs (productivity losses due to sick leave, absenteeism and early retirement; Andlin-Sobocki et al., 2005). The study showed that 127 million Europeans suffer from brain disorders, at a cost of €386 billion in 2004 (Andlin-Sobocki et al., 2005). In another study, brain disorders were estimated to constitute 35% of the burden of all diseases in Europe in 2003 (Olesen & Leonardi, 2003). According to the World Health Organization (WHO), mental disorders imposed the highest burden on European society, followed by cardiovascular diseases (CVD) and cancer (Table 1), even though many brain disorders were not included. The burden of disorders was measured in DALY (WHO, 2004).

Table 1. Top five disease groups in terms of burden of disorders in Europe (2002)

<table>
<thead>
<tr>
<th>Disease Group</th>
<th>EU-25 countries</th>
<th>EU-15 countries</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Per 1000 (%)</td>
<td>Total Per 1000 (%)</td>
</tr>
<tr>
<td>Mental</td>
<td>14 857 720 32.8 25.3</td>
<td>12 379 282 32.7 26.3</td>
</tr>
<tr>
<td>CVD</td>
<td>10 088 093 22.2 17.1</td>
<td>7 637 493 20.1 16.2</td>
</tr>
<tr>
<td>Cancer</td>
<td>9 839 035 21.7 16.7</td>
<td>7 989 864 21.1 16.9</td>
</tr>
<tr>
<td>Injuries</td>
<td>5 099 011 11.2 8.7</td>
<td>3 644 620 9.6 7.7</td>
</tr>
<tr>
<td>Respiratory</td>
<td>3 523 243 7.8 5.9</td>
<td>3 167 675 8.4 6.7</td>
</tr>
<tr>
<td>All disease groups</td>
<td>58 807 846 129.7 100.0</td>
<td>47 092 868 124.2 100.0</td>
</tr>
</tbody>
</table>

Brain disorders are therefore prevalent and costly to society, yet they receive only 15% of direct healthcare spending (Andlin-Sobocki et al., 2005).

These cost data (Andlin-Sobocki et al., 2005) on the burden of brain disorders support the results of the 1990 WHO/Harvard University Global Burden of Disease Study (Murray & Lopez, 1996), which emphasized the need for new initiatives to ensure optimal treatment of brain disorders, including initiatives in R&D. Today, brain disorders represent the single largest future indication for drug treatment [Centre for Medicines Research International (CMR), 2006]. An important recent initiative for the advancement of brain research was the creation of the EBC in 2002. The EBC unites neurologists, psychiatrists, psychologists, neurosurgeons, basic neuroscientists, patient organizations and industrial researchers with the primary purpose of promoting brain research (European Brain Council, 2006).

It is widely recognized that funds for brain research are important for the development of new therapies and to increase knowledge about brain disorders (Olesen & Leonardi, 2003). However, to our knowledge, no previous study has evaluated the size and nature of funding of brain research in Europe. In the cancer field, however, a survey was carried out in 2003 by the European Cancer Research Managers forum (ECRM; European Commission, 2005a), which estimated the total public funding of cancer research in Europe. For this survey, information was obtained directly from public funding agencies. The present study has adopted methods used in the ECRM study to estimate public funding of brain research. Estimates of industry spending on brain research in Europe have been obtained using methods similar to those used in a previous study (Wilking & Jönsson, 2005), which assessed the size of industry funding of cancer in Europe.

The present study is therefore pioneering because it identifies the major funding agencies of brain research in Europe and evaluates the size of the investments made in this field, as well as the potential benefits. It is our hope that this study will enable further investigation of research activity and the impact of different funding agencies. The primary objective of the study was to provide the best possible estimates of the funding of brain research in Europe. The secondary objective was to assess the potential benefits of increasing investment in brain research.

Publicly funded brain research was defined as investments made in brain research by both government agencies (public institutions) and charities (by the public and transparent to the public). Charitable organizations (organizations for public benefit that rely on donations for financial support) and private not-for-profit organizations (whose securities are not offered to the public) were combined into the term ‘charities’ to avoid any confusion.

The neurological disorders included in this study are: dementia (including Alzheimer’s disease), epilepsy, migraine, multiple sclerosis (MS), Parkinson’s disease (PD) and stroke. The two neurosurgical disorders are brain tumour and TBI. The psychiatric disorders: are addiction (alcohol and illicit substance dependence), affective disorders (depression, bipolar disorder), anxiety disorders (panic disorder, generalized anxiety disorder, social phobia, agoraphobia, obsessive–compulsive disorder, any specific phobia) and schizophrenia. As we wanted to estimate total funding of brain research, it was important to include a category known as ‘other brain disorders’ (e.g. amyotrophic lateral sclerosis, attention-deficit hyperactivity disorder, neurodegenerative disorders, etc.) and ‘basic research not related to specific disorders’.

For the purposes of this study, Europe is defined as the EU-25 (all the member states of the European Union) countries plus Norway, Iceland and Switzerland.
The number of organizations identified in each country varied between 0 and 34 (Malta and the UK, respectively), and the response rate between 0% (Poland and Slovenia) and 100% (Hungary, Ireland, Luxembourg and Switzerland).

Industry funding data

Data were collected using three previously published approaches for evaluating industry funding of cancer research (Wilking & Jönsson, 2005).

The first approach to assessing industry spending on brain research was based on the Centre for Medicines Research (CMR) International 2005/2006 Pharmaceutical R&D Factbook (CMR, 2006). This provides a clear picture of evolving trends in worldwide pharmaceutical R&D. Data were derived solely from primary sources that included all major pharmaceutical companies, which account for some 80% of the industry’s global R&D spending (CMR, 2006).

In 2002, the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlighted the increasing costs of developing a new drug or NCE over time (DiMasi et al., 2003). In this approach to determining pharmaceutical industry funding for brain research, total spending for each year was obtained by multiplying the number of brain NCEs by the cost of a single NCE in that same year.

The total research investment by pharmaceutical companies in Europe has risen more than seven-fold over the past 20 years, and doubled over the past 10 years, to reach €18 800 million in 2001 as compared to €7800 million in 1990 (EFPIA, 2002). In 2004, research expenditures had increased to €21 100 (EFPIA, 2006). Between 1985 and 2004, 9.54% of all the NCEs that entered the market were drugs for brain diseases. Assuming that this proportion of brain drugs to total NCEs reflects the R&D spending on brain research in Europe, a third measure can be constructed.

Comparative data

Data from the US were mainly obtained from NIH [National Institutes of Health (NIH), 2005], but also from the published literature (Hamilton et al., 2005) and electronic sources [Federal Reserve Bank of New York (Federal Reserve), 2004; Inflation Data, 2005].

Data on the funding of cancer research were taken from the ECRM study (European Commission, 2005a) and the oncology report by Wilking & Jönsson (2005).

Data on burden of disorders

The data on burden of disorders were taken from the published literature written in English. This included disorder-specific QoL estimates (Essink-Bot et al., 1995; Messori et al., 1998; Schrag et al., 2000; Foster et al., 2002; Stein et al., 2002; Prieto et al., 2003; Ravasco et al., 2003; Tengs & Lin, 2003; Andersen et al., 2004; Vles et al., 2005; Kobelt et al., 2006; Sobocki et al., 2006b) as well as prevalence (Andlin-Sobocki et al., 2005) and cost estimates (Andlin-Sobocki et al., 2005; Wilking & Jönsson, 2005) for different disorders. Data for the burden of brain disorders (i.e. cost-of-illness and prevalence) were taken from the final results of the ‘Cost of Disorders of the Brain in Europe’ study (Andlin-Sobocki et al., 2005).

Method for estimating the size of investments

Public funding

The method used in the ECRM survey (European Commission, 2005a) was used for estimating public brain research spending, i.e. funding agencies were contacted directly and asked to provide data on their research spending. Using this method, research spending from European funding institutions was estimated, rather than total research spending at European research institutions (which might also receive funding from foreign research funding agencies such as NIH). There is no certainty that research spending is spent in Europe, only that it is spent by European institutions. There is no data on the net effect of research funding and research production for Europe, but it is reasonable to assume that it will not significantly affect the estimates. Research funding by European agencies and actual resources used for research will be very closely linked. There are two major reasons for measuring funding and not actual research resources. The first is that it is easier to identify funders and their allocation of expenditures than it is to identify research institutions and their resource allocation. The second is that research funding is more relevant from a public policy perspective, as funding determines the magnitude and direction of research activity.

The results from the funding survey have been corrected for purchasing power by using Eurostat’s comparative price level (CPL) index (Eurostat, 2006a), to enable a comparison across European countries. Nevertheless, the data received were rather scarce for some countries due to the poor response rate. To cope with this and to assess a probably more reasonable estimate for the whole of Europe, imputations were made based on the countries whose major funding agencies provided the most comprehensive responses. These were: Austria, Belgium, Denmark, Estonia, Finland, Germany, Hungary, Iceland, Ireland, Luxembourg, Netherlands, Norway, Sweden, Switzerland and the UK. An average of these countries’ brain research expenditure per capita was used as a base case for imputing values to the other countries. The imputation index used for the base case was based on the countries’ R&D expenditure per capita (Eurostat, 2005c,d,f).

The original indices used in base cases were both altered to have the 15 countries with the most comprehensive responses as references. Sensitivity analyses were made on different types of indices as the basis for the imputations. These include indices based on spending as a percentage of GDP, health expenditure (Eurostat, 2006b; OECD, 2005) and CPL (Eurostat, 2006a) for all countries, as well as for reference countries as bases for indices, with and without outliers.

All results presented over different organizational types and disorders were based on data received from funding agencies. These data were then altered to relate to the total estimate from the imputed values.

Industry funding

The pharmaceutical industry accounts for the overwhelming majority of all industry research funding (CMR, 2006). However, due to lack of data, the exact contribution to brain research funding of industry organizations other than pharmaceutical companies cannot be determined.

The first attempt to assess the spending in Europe on brain research was based on a worldwide survey of pharmaceutical expenditure by disease area (CMR, 2006), assuming the share spent on brain research to be the same in Europe as in the rest of the world. This assessment was used as the comparative estimate for public spending on brain research, because it provides a complete overview of emerging trends in worldwide pharmaceutical R&D. From this estimate, it was possible to narrow down the funding allocated to each brain disorder using the
number of NCEs that have entered the market between 1985 and 2004. [Personal communication with Läkemedelsverket provided the list of all human NCEs that entered the European market over 20 years. The complete list can be provided upon request. See appendix to present study at http://www.europeanbraincouncil.org/publications for details on R&D calculations and NCEs.] Data provided by the CMR Factbook were, however, expressed in US$ for 2004; using the Federal Reserve (2004) data; we therefore obtained the mean of the foreign exchange rate between the US dollar and the Euro in 2004 [an exchange rate of 1.24 US$/€ was used] and inflated to 2005 values (Inflation Data, 2005). Country-specific estimates of industry funding were calculated using the estimate for industry funding and the distribution of industry R&D spending provided by EFPIA (2006), using the assumption that brain research spending is distributed in the same way as total R&D and that countries for which there are no data have no private R&D.

We then considered the cost of developing a new drug and the number of NCEs that entered the European market, giving an estimate of the industry spending supporting the new drugs entering the European market, regardless of where this money was spent. The NCEs included in this study were those that were specific to a disorder and that had been verified by a panel of experts.

The third method used to assess industry funding of brain research was to estimate total R&D expenditure by pharmaceutical companies in Europe on brain research as a proportion of total research expenditure. This approach highlighted research spending by the European pharmaceutical industry, regardless of whether the spending resulted in products marketed in or beyond the EU.

In the study of industry funding, it was assumed that all drugs listed as brain drugs [see appendix to present study http://www.europeanbraincouncil.org/publications for list of NCEs] were used exclusively to treat a specific brain disorder. According to this definition, TBI, also known as closed head injury, did not have any drug.

Method for drawing comparisons with US brain research funding and cancer research funding

The estimate of total funding of brain research in the US was based on a publication by Hamilton et al. (2005) and data from NIH (2005). Total US spending on biomedical research and the proportion of spending on biomedical research by NIH and other sectors were analysed (Hamilton et al., 2005). For the present study, it was assumed that the same proportion of spending on research by different sectors was applicable to the brain sector. Based on NIH data for 2004 (NIH, 2005), it was possible to estimate total funding of brain research in the US, inflate it to 2005 values (Inflation Data, 2005) and convert it to Euros (Federal Reserve, 2004). As the US and Europe differ in size of population and GDP, a comparison of spending was made also in relation to these parameters.

The ECRM study (European Commission, 2005a) and the oncology report by Wilking & Jönsson (2005) used very similar methods, which were found to be suitable for supplying comparative data on cancer research spending. Total funding and the relative contribution from different funding bodies to the total were compared for cancer and brain research. The data obtained from the two previous cancer studies (European Commission, 2005a; Wilking & Jönsson, 2005) were for 2003 and were hence inflated to 2005 values using the EU-25 annual average rate of change as provided by Eurostat in the harmonized indices of consumer prices (HICP) (Eurostat, 2005e). To provide a perspective on the relative size of investments in the brain and cancer fields, selected data on the burden of the two groups of disorders (Olesen & Leonardi, 2003; WHO, 2004, 2006; Andlin-Sobocki et al., 2005; Wilking & Jönsson, 2005) were presented.

Comparison with cost of brain disorders

In the late 1990s the Institute of Medicine was appointed to ‘do a comprehensive study of the policies and processes used by NIH to determine funding allocations for biomedical research’ (Institute of Medicine, 1998). In the recommendations the Institute of Medicine made to the ‘Priority Setting Document’ for research funded by NIH, it stressed the importance of considering public health needs. It was stated in the study that NIH should pay greater attention to the burden of illness in assessing priorities for research to meet public health needs.

This type of method is not a full economic evaluation in the strict sense described by Drummond et al. (1997); rather, it gives an idea of whether the amount spent on research could be returned through a reduction in the economic cost of brain diseases. In the present study, the burden of brain disorders was compared to funding of research. To illustrate this relationship, calculations were made on disorder-specific research funding as a percentage of the cost of the disorder. The results from the public funding survey of research spending on different groups of disorders were also compared to the equivalent costs.

Assessment of benefits from brain research

Medical improvements and discoveries are generated by investments in medical research. However, it is difficult to identify, measure and value the benefits gained from medical innovations. Several methods were therefore applied to assess the benefit of investments in brain research: (1) by presenting case studies from the published literature in order to illustrate how medical interventions can lead to improvements for different disorders; (2) by illustrating future trends in brain research; and (3) by assessing the equivalent research investment value of the potential QoL increase due to medical innovation.

Individual brain diseases were studied to illustrate the benefits of medical research and development. Medical innovations offer new and hopefully better treatments, increasing QoL and leading to a reduction in the cost of diseases to society. Medical innovations include new technologies for diagnosis, surgical techniques, radiotherapy, psychotherapies, physical therapies and drugs. Drugs constitute the majority of such innovations. New medicines have been shown to improve health and QoL, and to prevent or reduce the risk of illness (e.g. vaccines) (Pharmaceutical Research & Manufacturers of America, 2006). The case studies presented here were therefore chosen to illustrate the effects of new drugs. Data for the different cases were retrieved from the published literature and the cases were selected according to how representative a picture they provided of the effects of medical innovations. Four different disorders were chosen, to illustrate major disease-specific changes due to improved treatments. The present study then expanded on the benefits seen in those specific cases to emphasize the need for further improvements in the future.

In this study, the burden of disorders was expressed in DALY. However, when estimating the value of a potential future benefit, quality-adjusted life years (QALY) were used instead. In DALY, disability and mortality measures are combined whereas, in QALY, QoL measures are combined with mortality measures. The advantage of measuring the benefits of brain research in QALY is that it can easily be compared with all diseases, regardless of their nature (i.e. irrespective of whether the major impact of the disease is on longevity or QoL). Calculations were hence needed to estimate the impact of
brain disorders on QALY. Subsequently, calculations were made to evaluate the equivalent of an increase in QoL and QALY in terms of investment.

The QoL estimates retrieved from the published literature in the English language had to have been obtained using EuroQol in five dimensions (EQ-5D; Richards & de Wit, 2004) for coherence and comparability. [EQ-5D is a short self-report questionnaire designed to measure generic health-related QoL; the five dimensions are: mobility, self-care, usual activity, pain/discomfort and anxiety/depression. Each dimension is measured by one item and scored between 0 and 1 (where 0 equals death and 1 perfect health). It also includes a 0–100 graphic rating scale to measure overall health status, called Visual Analog Scale (EQ-5D VAS.)] The disorder-specific estimates were assumed to be representative for the whole European population, even though data were only estimated based on one country. If a mean EQ-5D estimate was not available, the EQ-5D visual analog scale (VAS) was used as a proxy. A potential QoL increase was simply assumed and the QoL value of the increase was multiplied by the prevalence to give the total value of the QoL increase for the whole affected population. As the timeframe was set at 1 year, this estimate would equal the total amount of QALY gained.

To evaluate the QoL increase in monetary terms, we used an estimate of willingness to pay (WTP) for a QALY. According to standard economic principles, WTP for gains in health and longevity is determined by how much changes in life expectancy and QoL affect the discounted present value of lifetime utility, among other factors. Given the life cycle pattern of health, and the survivor function, the expected lifetime utility for a representative individual can then be estimated. Point estimates of the WTP for a QALY range from $50 000 to $100 000 in the literature (Goldman et al., 1992), but results from Murphy & Topel (2003) and Johnston et al. (2006) show that the value of health benefits for many diseases greatly exceed the investments made, when testing for lower WTP ranges for a QALY. In this study, we assessed the threshold discussion initiated by WHO. The WHO Commission on Macroeconomics and Health (WHO, 2001a) suggested that interventions in undeveloped countries should be considered good value for money if the cost-effectiveness ratio is lower than three times the GDP per capita. The present study uses somewhat different guidelines because it is European and uses QALY as an outcome measure (rather than DALY as in the WHO report). Nevertheless, as discussed by Borgström et al. (2006), this should not significantly alter the results and a reasonable level for the WTP could be two times the GDP per capita, or almost €46 000 for Europe.

Results

Total funding of brain research

The total funding of brain research in Europe was estimated at €4.1 billion in 2005, of which the public sector contributes €855 million. Industry therefore invests €3.25 billion in brain research, or 79% of the total funding. The range of industry funding estimates is €2.7 to €3.9 billion. The estimate provided by the CMR, €3.25 billion, was used as the primary comparative estimate (CMR, 2006).

Figure 2 shows the distribution of research spending over groups of brain disorders, plus the investment made in basic research and research on other brain disorders.

Public funding

The results of the public funding survey indicate that total spending by public institutions and charities in Europe in 2005 amounts to an estimated €855 million, of which the EC contributes €94 million (Fig. 3). The EU-15 countries (the members of the European Union prior to 2005) account for 91% of total spending. Average spending per country was €27 million, with a median of €6.6 million (the EC excluded). However, the absolute spending estimates on brain research varied greatly across countries, from €60 000 to €312 million (Malta and the UK, respectively).

The results of the sensitivity analysis produce a range of estimates between €743 million and €1063 million, depending on which indices were used for imputation and price adjustments.

Spending per capita in Europe was €1.82. The average spending per capita included in the study was €1.28 in all European countries and €1.70 in the EU-15. Figure 4 illustrates European country-specific public brain research spending per capita in 2004. The highest spending per capita was in Ireland, with €6.73 per capita, and the lowest in Latvia, with €0.14 per capita.

Total spending in Europe as a percentage of GDP was 0.008%. The highest spending on brain research as a percentage of GDP was in Hungary, with 0.0215% of GDP, and the lowest in Malta, with 0.0009% of GDP. Average public spending as a percentage of GDP, which was included in the study, was 0.0055% in all European countries and 0.0067% in the EU-15.

Charities accounted for 22% of the total spending reported on brain research in Europe in 2005. It should be noted that the UK’s Wellcome Trust spent over €800 million, which is 52.5% of the total reported spending by charities in all of Europe. Table 3 illustrates the top five brain research funding charities. The average reported spending by charities is €688 369 (excluding the Wellcome Trust), and 78% of the charities reported a research spending below €1 million.

The funding body which contributes the most by far, among government agencies, is the group of UK Research Councils (Medical Research Council, 62%; Biotechnology and Biological Sciences Research Council, 26%; Engineering and Physical Sciences Research Council, 9.5%; Economic and Social Research Council, 2.5%), which accounts for €191 million (41.4% of the total reported government funding). Table 4 illustrates the top five brain research funding government agencies. The average reported spending by government agencies was £5.7 million (excluding UK Research Councils), and 40% of the government agencies reported a research spending below €1 million.

Basic research not related to specific disorders accounts for 47% of total spending. Together, the 12 most prevalent brain disorders account for some 39.4% of the total public funding of brain research (Fig. 5). The category ‘Other brain disorders’ accounts for 13.6% of total spending. By specific disorder, the total public spending ranges from €7 million for migraine to €57 million for dementia, with an average of €28 million per disorder.

Eighty-seven per cent of the funding of basic research not related to specific disorders comes from government agencies.

Mental disorders accounted for 32% of total public spending on disorder-specific research and neurological disorders accounted for 58%. Neurosurgical disorders accounted for 10% of public research spending.

Universities are not included in our analysis because it turned out to be hard for them to account for which resources are invested in brain research. Hence their inclusion would have brought with it a high risk of double-counting the financial resources used for research. Uppsala University in Sweden serves as an example of what research funding at a university looks like. In the university’s neuroscience department, about one-third of the research funding comes from external sources such as the Swedish Research Council and various charities. The rest
comes from a base grant from the government and from small foundations belonging to the university itself. The total budget for the neuroscience department at Uppsala University is €10 million, €4 million of which come from the base grant and in-house foundations (about half each) for research. According to an internet-based directory of universities (Braintrack, 2006), there are almost 700 universities in Europe today. Many of these are not involved in the medical sciences and not all are funded in the same way or to the same extent as Uppsala University. Nevertheless, if 200 is a fair guess of the number of universities involved in brain research, and if Uppsala University’s spending is representative in Western Europe, while Eastern European countries spend half of that, then an additional €700–800 million should be added to the total research spending estimate. However, as we do not know how large the overlap is between university spending on research and the total research spending estimate excluding universities, we have chosen not to include this figure in the base case comparisons.

Industry funding
The three different estimates of industry funding gave a range of €2.7–3.9 billion being invested in brain research per year by the pharmaceutical sector of industry.

In 2004, global pharmaceutical R&D expenditures reached US$56 billion worldwide, and brain disorders accounted for 15.4% of total R&D expenditures, or US$8.6 billion. Europe accounted for about 45.9% of total R&D expenditures in 2004 (CMR, 2006). According to this estimate therefore approximately US$3.96 billion (€3.2 billion; Federal Reserve, 2004) were spent on brain research in Europe in 2004. We inflated the values to 2005 (Eurostat, 2005e), resulting in a total estimate of €3.3 billion.

Country-specific estimates of industry funding (Fig. 6) were calculated by using the estimate for industry funding and the distribution of industry spending provided by the EFPIA (EFPIA, 2006). As with public funding, there is a big difference in industry funding between the highest and lowest funding countries, ranging from the UK with €737 million to Greece with €5.5 million (note that some countries included in this study have no industry funding registered in the EFPIA report, and hence are assumed not to have any industry funding in brain research either).

Using the next estimate, in which we considered the cost of developing new drugs and the number of NCEs on the European market, we were able to estimate industry spending on brain disorders in a disease-specific way (Table 5 and Fig. 7). [See appendix to the present study at http://www.europeanbraincouncil.org/publications for details on NCE calculations.]

Figure 8 shows how industry funding of brain research has varied over the past 10 years. As shown in Fig. 8, not all brain diseases have seen their research spending increase over time. Indeed, research spending on MS, PD...
Fig. 3. Public brain research spending by country, including the EC (€, 2005). *Reference countries for imputations.

Fig. 4. Country-specific public brain research spending per capita (€, 2005). *Reference countries for imputation. See the appendix to present study for details on spending in reference countries by organization type [http://www.europeanbraincouncil.org/publications].

© The Authors (2006). Journal Compilation © Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 1–24
and stroke has been significantly reduced over the past five years. No funding at all was reported for research on anxiety disorders or TBI.

One potential reason for these discrepancies is the chosen method of estimation, which depends on acceptance of NCEs that have entered the European market during these periods, rather than actual input for research. [See appendix to the present study at http://www.europeanbraincouncil.org/publications for details on calculations of industry funding.] The distribution across disorders also represents previous research investments rather than investments for the year of the NCE’s market entrance. As noted earlier, only drugs specific to each brain disorder were used in the present study, and other NCEs related to brain diseases were not taken into account.

In 2002, EFPIA highlighted the increasing costs over time of developing new drugs (EFPIA, 2002). The cost of developing a new drug has been estimated in 1993, 1997 and 2003 at €307 million, €378 million and €895 million, respectively (EFPIA, 2002). This results in a cumulative investment of approximately €37 billion total spending over 19 years (1985–2004) to develop all new brain drugs, an average of almost €2 billion per year. Over the last five years, the estimated average annual spending on brain research by the pharmaceutical industry is about €3.8 billion, or €3.9 billion at 2005 prices (Eurostat, 2005e).

R&D investments by pharmaceutical companies in Europe have doubled over the last 10 years from €7800 million in 1990 to €18 800 million in 2001. Over the last 20 years (see Fig. 9), R&D...
spending by pharmaceutical companies in Europe has risen more than seven-fold (EFPIA, 2002). Between 1985 and 2004, 9.54% of all NCEs that entered the market were drugs for brain disorders (74 of 776 NCEs were classified as brain drugs). This means that the R&D expenditure for brain research over 19 years (1985–2004) can be estimated at €28.1 billion, or €2.6 billion per year over the last five years, which is €2.7 billion at 2005 prices (Eurostat, 2005e).

Comparative data

Comparison with the US

In 2003, NIH contributed 67.2% of the total public investments in biomedical research in the US (Hamilton et al., 2005). Total spending by NIH on brain research in 2004 was US$4.9 billion (NIH, 2005) or €3.95 billion [Exchange rate 1.2439 US$/€ (Federal Reserve)]. Total public spending on brain research therefore amounted to almost €5.9 billion for 2004, assuming that the share for brain research of biomedical research outside NIH is the same as it is within NIH. With an inflation rate of 3.39%, spending in 2005 will be €6.1 billion, which should be compared to the public spending in Europe of €855 million. US public funding of brain research is therefore more than seven times European funding (Fig. 10). It should be noted that the US also dominates other medical fields. For example, US public spending on cancer research (NIH, 2005; Hamilton et al., 2005) is more than four times European spending (European Commission, 2005a). In diabetes, US public spending is more than 13 times European public spending (Halban et al., 2006).

We have estimated the European industry funding going to brain research at €3.25 billion, or 79% of the total funding. The corresponding figure for the US is $8.1 billion, or 58% of the total funding (NIH, 2005; Hamilton et al., 2005). Charities only constitute 6.5% of the total funding from US public institutions, and NIH is the single largest contributor to research, with 28.3% of total funding (67.2% of the funding from public institutions). In Europe, on the other hand, charities contribute 22% of the total funding from public institutions even though, in absolute terms, European charity funding is substantially smaller than charity funding in the US.

When research investments are expressed in relative terms, the US still dominates Europe. In 2004, total spending on brain research as a percentage of GDP was 0.153% in the US, four times the equivalent European estimate of 0.037%. Public spending on brain research per capita was €1.8 in Europe and €20.8 in the US (Eurostat, 2005f; NIH, 2005). When looking at these estimates, the gap between the US and Europe appears larger than when looking at absolute values.

In terms of government spending, NIH outspends Europe in all brain disorder categories by at least four times, except in migraine and anxiety disorders. Total European government spending constitutes 12% of NIH spending on brain research. The largest difference in spending is in addiction and the smallest in epilepsy, although there is a significant difference across all disorders. European government

![Fig. 7. Industry funding of brain research by disease area in €, 2005.](image)

![Fig. 8. Annual industry funding of brain research by disease area in € million in Europe with a five-year interval (1985–2004). The 2005 estimate from the CMR Factbook was used and deflated to previous years to obtain the most accurate assessment possible for 1995–99 and 2000–04.](image)
spending as a percentage of NIH spending by disorder is illustrated in Fig. 11. It should, however, be noted that data for NIH are not exclusive, and could therefore be partly overlapping. According to NIH data (NIH, 2005), research on drug abuse and alcoholism were accounted for separately and their sum exceeded NIH research spending on substance abuse. As there is a risk of overlap in these data, the estimate for substance abuse was used.

Comparison with cancer research

The estimated funding of cancer research and brain research in Europe are strikingly close to each other in terms of total funding (Table 6). However, in relation to total cost of disease and the burden of disease as measured by DALY lost, funding for brain disease is significantly smaller. The research expenditure per death is significantly higher for brain disorders, as a large portion of the disease burden is attributable to morbidity and not mortality.

Industry funding of brain research (£3.25 billion) is larger than industry funding of cancer research (£2.5 billion; Wilking & Jönsson, 2005), but cancer research claims a higher total public investment. As illustrated in Fig. 12, investment in research by the government sector is almost the same for both. However, cancer charities contribute almost four times more to research than do brain research charities.

Research funding in relation to cost of different brain disorders

The total cost of brain disorders was estimated at £386 billion in 2004 (Andlin-Sobocki et al., 2005). The majority of the costs of brain disorders were indirect costs due to morbidity. A big part of the costs, for example, were due to lost working ability (sick leave and early retirement), particularly in mental disorders such as depression. The costs of social services and informal care were also high, especially in dementia and MS. Mental disorders accounted for 67% of the total costs of brain disorders. The most costly brain disorders were depression, dementia and addiction.

The total funding for brain research estimated in the present study amounts to 1% of the total cost of brain disorders (Andlin-Sobocki et al., 2005). Public funding makes up 0.2% of the total cost of brain disorders, and industry funding 0.8%. Figures 13 and 14 illustrate the relationship between public spending and the costs of brain disorders. For the specific disorders, the range is 0.02–0.5% of the costs (migraine and brain tumour, respectively). Brain tumour and TBI are relatively rare compared to other brain disorders, but very costly per case. Migraine and mental disorders (affective disorders, anxiety disorders, addiction and schizophrenia) are common and represent a heavy monetary burden on society, but receive less public funding relatively.

The range for industry funding is 0.2–3.6% of the costs (anxiety disorders and PD, respectively). [TBI is not included in these calculations as there is no industry funding attributable to this disorder.] Mental disorders and dementia are the least funded disorders...
in terms of industry funding in relation to their societal cost. PD and epilepsy receive the most funding from industry, relative to their cost to society, followed by MS and stroke. In absolute terms, affective disorders is the group of disorders that receives most funding from industry in Europe, at €571 million. Epilepsy and PD both get almost €400 million. Least funding, in absolute terms, is dedicated to anxiety disorders and brain tumour.

Mental disorders account for 69% of the total cost of brain disorders in Europe, whereas the public spending on mental disorders accounts for 32% of the total (Fig. 14). For neurological diseases the pattern is the reverse: they account for 29% of the costs but receive almost 60% of the public funding. Neurosurgical diseases (brain tumour and TBI) account for 2% of the total cost of brain disorders and receive 10% of the total public funding. Industry funding shows a similar pattern, except for neurosurgical disorders which only account for 1% of the funding. Mental disorders receive 37% and neurological disorders 62% of total industrial funding, respectively.

**Benefits from brain research**

*Benefits from medical innovation in the past*

The following are examples of specific benefits obtained from medical innovation in the area of brain diseases. Four disease areas have been chosen to illustrate how, in the past, medical innovation has improved the situation both for the patient and for society.

**Reduced burden on community and caregivers.** Many people afflicted with a brain disease are dependent not only on formal healthcare, such as that provided by physicians and specialists, but also on community care and informal caregivers (e.g., partners, family and friends). Dementia is a good example of a brain disease where community and informal care are important components of the cost of the disease (Jonsson, 2003). These caregivers become increasingly important as dementia progresses to severe states (Jonsson, 2003). Andlín-Sobocki *et al.* (2005) showed that the majority of the total estimated costs of

---

**Table 6. Research funding, costs, deaths and burden of cancer compared to brain disorders in Europe (2005)**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Burden of disease</th>
<th>Funding relative to burden</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Funding (million €)</td>
<td>Costs (million €)</td>
</tr>
<tr>
<td>Cancer</td>
<td>3 996&lt;sup&gt;a,f&lt;/sup&gt;</td>
<td>226 486&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Brain disorders</td>
<td>4 107</td>
<td>389 364&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

The cost estimates are based on 19 European countries as stated in Wilking & Jönsson (2005) for comparability. The cancer cost estimate assumes that indirect costs are three times the direct costs, giving a relatively high estimate (see Discussion in Wilking & Jönsson, 2005). The cost estimate is also inflated to 2005 year values. The death estimates exclude Cyprus. Source references: <sup>a</sup>Wilking & Jönsson (2005); <sup>b</sup>Andlin-Sobocki *et al.*, 2005; <sup>c</sup>World Health Organization (2006); <sup>d</sup>World Health Organization (2004); <sup>e</sup>Olesen & Leonardi (2003); <sup>f</sup>European Commission (2005).
Fig. 12. Public funding of brain and cancer research in million Euro in Europe (2005). Source: Public cancer research funding figures (European Commission, 2005a); industry cancer research funding figures (European Commission, 2005a; Wilking & Jönsson, 2005). Cancer estimates were for 2003 and are hence inflated to 2005 values.

Fig. 13. Public brain research funding as a percentage of costs by brain disorder (2005). ‘Total’ represents the total estimate of public funding of brain research.
dementia in Europe, €55 billion, were due to community care and informal care. These accounted for 56 and 20% of the total cost, respectively, or €41 billion together (Fig. 15).

A number of new drugs have become available for the treatment of dementia. Cholinesterase inhibitors (donepezil, rivastigmine and galantamine) have entered the market in recent years. They can help improve the cognitive function and behaviour of patients, and may delay the progression of dementia (Jonsson, 2003). The most recent medical innovation is memantine, an NMDA receptor antagonist. Model assessments have indicated that cholinesterase inhibitors could decrease the cost for the community and informal care of demented persons (Jonsson, 2003, 2005; Wimo et al., 2003), and also delay the costs relating to later stages of the disease (e.g. costs associated with institutionalization). Moreover, a number of studies have shown that these new medical technologies are cost-effective if not even cost-saving compared to giving no treatment. Economic evaluations of these drugs indicate that there are potential offsets in terms of community care costs and reductions in caregiver time (Wimo et al., 2003). At the present time, however, there is no treatment that stops the progression of dementia. In summary, there is a growing body of evidence suggesting that new treatments are often connected with substantial cost savings, especially in terms of community and informal care.

**Improved working ability.** Most brain disorders start at an early age and have a significant impact on a person’s ability to work. The cost of loss of productivity and mortality due to brain disorders has been estimated at almost €80 billion per year in Europe (Sobocki et al., 2006c), or almost half the total cost of those disorders. Depression is a good example of a disease which disables the patient for long periods of time and makes it difficult for him or her to remain in the workforce (Paykel et al., 2005). Moreover, depression has a lifelong recurrent or chronic course (Paykel et al., 2005), which may lead to long-lasting absence from the workforce or even early retirement. Sobocki et al. (2006a) found that depressed patients have, on average, 1.5 months of sick leave during a depressive episode, which represents a six-monthly cost of almost €4000. There were statistically significant reductions in number of sick leave days and related costs for patients who had been successfully treated to remission (Sobocki et al., 2006a).

In the last decade, a range of new antidepressants has become available which has changed the outlook for depressed patients. A convincing number of studies now suggests that antidepressants are cost-effective (particularly the selective serotonin re-uptake inhibitors and newer antidepressants) in reducing the burden of depression (Barrett et al., 2005). Recent studies also indicate that these new

---

**Fig. 14.** Division of spending and costs by group of disorders (2005).

**Fig. 15.** Distribution of the cost of dementia in Europe. Source: Andlin-Sobocki et al. (2005).
therapies are associated with substantial savings in terms of reduced productivity loss (Simon et al., 2000; Peveler et al., 2005; Sobocki et al., 2006a). Sobocki et al. (2006a) have shown that more than half of patients achieve remission from a depressive episode through treatment with selective serotonin re-uptake inhibitors over a six-month period, and that statistically significant reductions in costs due to sick leave are observed. The same authors have estimated the cost saving to be in the range of €2000 per successfully treated patient. This finding is in line with previous findings in the literature (Simon et al., 2000). Hence there are strong indications from the literature that medical innovations for treating depression have improved the chances that patients will return to employment faster, and so reduced the cost of the disease.

**Improved health-related quality of life.** Brain disorders have an enormous impact on health-related quality of life which is often neglected when the cost of the disease is estimated (Andlin-Sobocki et al., 2005). MS is an example of a brain disease with a substantial impact on a patient’s daily living and QoL (Kobelt, 2004). MS, which affects people early in life and often leads to severe functional disability, is the second most common cause of neurological disability in young adults (Kobelt, 2004).

Health-related quality of life is defined as the impact on an individual’s well-being of his or her health, and it often encompasses physical, mental and psychological elements (Kobelt, 2002). Disability from MS reduces QoL (Kobelt et al., 2006) as patients frequently have to endure health problems such as bodily pain as well as low vitality. This negative effect on patients’ ability to perform normal daily activities leads to a significantly lower QoL (Kobelt, 2003). Measures with the generic EQ-5D instrument (EuroQol-Group, 1990) show that patients with severe MS (i.e. wheelchair-bound) rate their own QoL as reduced by more than half compared to a person with perfect health (Kobelt et al., 2006), whereas QoL ratings of patients with the mildest forms of MS are closer to those of the general population. Hence, there are substantial gains to be made in terms of disability and QoL by slowing the progression of the disease, even if it cannot be stopped entirely.

In terms of medical innovation in MS treatment, there has been a breakthrough with the introduction of interferons. Interferon treatments are associated with significant delays in the time to confirmed progression of MS (Kappos et al., 1998; Kobelt et al., 2000, 2002). Although they are expensive, there is growing evidence that interferons are cost-effective in the management of MS patients (Kobelt et al., 2000, 2002).

**Table 7. Therapeutic area breakdown of active substances in development for first launch in Europe (2004)**

<table>
<thead>
<tr>
<th>Therapeutic area</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous system</td>
<td>22.5</td>
</tr>
<tr>
<td>Oncology and immunomodulators</td>
<td>18.3</td>
</tr>
<tr>
<td>Alimentary and metabolism</td>
<td>13.0</td>
</tr>
<tr>
<td>Cardiac</td>
<td>9.3</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>8.8</td>
</tr>
<tr>
<td>Respiratory</td>
<td>8.1</td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>7.8</td>
</tr>
<tr>
<td>Blood</td>
<td>3.9</td>
</tr>
<tr>
<td>Other*</td>
<td>8.3</td>
</tr>
</tbody>
</table>

Source: CMR Factbook (CMR, 2006), chapter 4, page 42. *Includes GU/sex hormones (4.8%), dermatological (1.3%), sensory (1.1%), antiparasitics (0.8%) and hormones (0.3%).

**Future treatments and benefits of research investments**

The CMR Factbook presented the proportion of all active substances in development by therapeutic area in 2004, for a total of 841 drugs (CMR, 2006). Drugs were allocated to therapeutic areas based on the indication under investigation, using the WHO’s anatomical therapeutic chemical classification system (ATC codes). The analysis excluded drugs for which the mode of action was not provided. Table 7 illustrates the percentage of drugs in the developmental pipeline by therapeutic area.

The top five therapeutic areas in terms of the number of active substances in the pipeline are the central nervous system (CNS), oncology, alimentary and metabolism, CVD and musculoskeletal diseases. Together they account for 70% of all drugs in development (CMR, 2006), the leading therapeutic area being the CNS with 22.5%.

Figure 16 illustrates the number of brain drugs that entered a specified stage of development in a given year (CMR, 2006). The preclinical phase covers active substances between the ‘first toxicity dose’ and the ‘first human dose’, phase I between the ‘first human dose’ and the ‘first patient dose’, phase II between the ‘first patient dose’ and the ‘first pivotal dose’, phase III between the ‘first pivotal dose’ and the ‘first submission’, and finally the regulatory review between ‘first submission’ and ‘first approval’ (CMR, 2006).

The last three years have seen a considerable increase in the number of new brain drugs entering phase I, while the number of brain drugs entering phase II has remained relatively constant.

The data provided in this report demonstrate that more patients in Europe are being diagnosed with a brain disorder (WHO, 2004), but the mortality rates due to brain disorders are not as high (WHO, 2006). This indicates that more patients are living longer with the disease. In the light of this, it is clearly in a patient’s best interests that innovative drug therapies should be made available as soon as possible after market authorization.

A number of treatments for brain disorders are under investigation. Clinical trials testing potential therapies are under way and other new treatments are being devised and tested. It is likely that many of these new brain drugs will be valuable tools for the medical treatment of brain diseases for many years after their patents have expired. We must remember that, for many of the drugs introduced just a decade or two ago, the patents will expire in the near future or generic versions are already available. According to the IMS LifeCycle Patent Focus (Class, 2004), for example, six major drugs are set to lose their US patent protection by 2007.

New therapies could save lives and improve the QoL of patients. However, it is hard to evaluate the benefits of medical innovation in general terms. Table 8 illustrates how much an increase in QoL for the European population affected by a brain disorder would equal in terms of research investment.

If we were able to improve the health status of all those affected by a brain disorder by 5% in a given year, this would amount to €180 billion in monetary terms. This value of increased QoL is only for one year and hence represents a minimum value of increased QoL (due to annuity being ignored in calculations). It is highly possible that the benefits of these improvements will prevail in the years to come. As the time for developing a new drug is approximately 10 years (EFPIA, 2002), the estimated value of the benefits would equal the yearly investments in brain research of €18 billion, which is to be compared to the total estimate of research funding in this present study of €4.1 billion. The results show that the value of this QoL increase exceeds the investment in research even at a lower WTP.
Discussion

Main findings

The estimate of the total spending on brain research in Europe in 2005 was €4.1 billion. Total public funding by government agencies and charities was €855 million, of which charity funding accounted for 22%. Fifty-three per cent of the public investment went to disorder-specific research. Sensitivity analysis of the estimations of public funding gave a range between €743 million and €1063 million. These figures potentially excluded university funding; including university funding in public funding would result in estimates up to €1.8 billion (neglecting the risk of double counting). Industry funding constituted 79% of the total funding. For all industries and R&D fields, the industry contribution was 54%. Industry funding of brain research was estimated at €3.3 billion, with a range from €2.7 to €3.9 billion.

Our results indicate that research funding is differently distributed across the specific brain disorders. Research on TBI receives the least funding and affective disorders the most (50 times that of TBI). Much evidence supports the finding that brain disorders impose a great burden on society and that brain research funding is nowhere near the costs of these disorders. Public investment in brain research has been shown to be particularly low, constituting 0.2% of the total cost of brain disorders. It is also low compared to investment in cancer research, and extremely low compared to the brain research funding in the US.

Our assessments show that large benefits have been gained from brain research over recent decades, both for individual patients and for society as a whole. There are indications that further investment would produce even greater benefits.

Methodological aspects

Estimating public funding of brain research

The method of using a funding survey to estimate public funding of brain research has previously been used successfully (European Commission, 2005a) in the cancer field. The results from the cancer study were therefore directly comparable to the results of the present study. We chose to collect information on funding for brain research...
directly from the primary sources of funding. There are two major reasons for measuring funding and not actual research resources. The first is that it is easier to identify funders and their allocation of expenditure than it is to identify research institutions and their resource allocation. The second is that research funding is more relevant from a public policy perspective, as funding determines the magnitude and direction of research activity.

The method employed posed a challenge in coping with missing data. Values were imputed for countries whose major funding agencies yielded an unsatisfactory response rate, to produce the best possible estimate of total funding of brain research in Europe. Country-specific data are therefore uncertain for many countries and should be interpreted with caution. Nevertheless, the present study provides a unique insight into the public funding of brain research and highlights a need for further national investigations to more adequately account for national spending in this area.

The public estimate used in the comparative analysis is probably the most accurate one, as it takes into account the CPLs for the reference countries and the level of the respective countries’ spending on R&D in general. The imputations might over-estimate countries’ spending, but it is also possible that the estimates on which they are based have been underestimated, as some funding organizations may have been overlooked (see Discussion on missing data).

Funding data broken down by disorder should be treated with caution. Approximately 80% of the funding agencies were able to break down their spending by disorder, but the rest did not keep such records. Moreover, many charities and government agencies distribute their research grants by application competition, so that the spread across disorders and sciences is different each year. Many funding agencies also stated that their investments in brain research are to increase in coming years. For example, some of the organizations identified made their first investment in brain research later than 2004 and were therefore not included.

Estimating industry funding of brain research
Three different methods were used to assess industry funding of brain research, and to provide the best possible estimates. The second estimate of industry funding of brain research was based on new drugs coming onto the European market between 1985 and 2004, regardless of where this money was spent, and reflects earlier spending. The third approach highlighted research spending by the European pharmaceutical industry, regardless of whether this funding resulted in products marketed beyond the EU, and the comparative figure was taken from the CMR International Factbook 2005/2006 (CMR, 2006). The CMR data were derived from primary sources and give a clear picture of upcoming trends in worldwide pharmaceutical R&D.

The share of industry research devoted to the brain has increased over time (as has the share of all health economic publications devoted to brain disorders). This suggests that our estimates of industry brain research funding are too low. On the other hand, not all drug development costs are for research, suggesting that our estimates are too high.

Using data on NCEs entering the European market between 1985 and 2004, an estimate of funding of each of the 12 most prevalent brain disorders was obtained. It should be noted, however, that only NCEs whose main therapeutic application was for a specific brain disorder were selected, and not all new drugs registered during that period were included. The spread of industry funding over disorders is therefore an average based on previous years. It is also important to note that the amount of time and the cost involved in developing new drugs varies across therapeutic areas.

Measuring the gains of brain research funding
The funding of brain research in relation to the cost of brain disorders was investigated. Though research funding may have been underestimated, total research investment constitutes a small fraction of the total cost of brain disorders (1%).

There is a methodological challenge in fully assessing the benefits of medical research at a general population level, particularly in the field of brain research where the range of disorders is broad and patient-level benefits are measured in terms of morbidity rather than mortality. Earlier studies have investigated gains from medical research in terms of mortality and QALY gains (Murphy & Topel, 2003; Johnston et al., 2006). For our purposes, different methods were chosen to illustrate historic gains from investments in brain research. First, illustrations were given of key benefits in specific brain disorders due to medical innovation. We chose substantial gains that have already been seen, to indicate that future innovations could potentially produce similar benefits. With an ageing population and people living longer, the importance of such innovations cannot be over-emphasized.

The WTP for increased QoL was also calculated, to see how much a given increase would represent in investment terms. Though the results from this assessment should be interpreted with caution, they indicate that current investments are substantially lower than the WTP for a 5% QoL increase.

Missing data on public and industry spending on brain research
Through the public funding survey, European funding agencies were directly contacted and asked to provide data on their research investments. There is, however, a possibility that organizations have been omitted, either because they have not been identified due to a lack of the necessary language skills (which is one potential explanation for the higher response rate in Western as opposed to Eastern European countries), and/or because of a failure to report data. These sources of error have been minimized with the help of national neuroscience societies. Imputations have been made for those countries whose major funding agencies produced an inadequate response rate. Moreover, the total estimate of brain research (and especially basic research not related to disorders) is probably underestimated. Universities are large and important research institutions, but it was hard to assess to which specific research areas their various funds were directed (internal and external funds). To minimize the potential for double-counting in funding, university funding was therefore excluded from our base case estimates. A rough estimate of university funding was reported, however, and it may be concluded that inclusion of university funding would not significantly alter the overall conclusions.

Stroke and brain tumour are listed under CVD and oncology, respectively, by the WHO. Research in these general fields may have had an impact on the understanding and treatment of brain tumour and stroke, though it is hard to assess how much. The contribution to brain research of ‘basic research not related to specific disorders’ cannot be included in the total estimate. However, this should not alter the comparison between disorders as ‘basic research not related to specific disorders’ is not divided between the brain disorders either.

Finally, during the assessment of drugs for specific brain disorders, carried out to estimate industry funding, it was concluded that there was no specific drug for TBI. It is regrettable that no drug development seems to target this serious and costly disorder that affects mainly young individuals.
Policy implications

Funding distribution within brain research

Individual brain disorders have sometimes been perceived as difficult to study because of their heterogeneity (Pendlebury et al., 2004). This remains a challenge in studies of funding of all major brain disorders taken together (Olesen et al., 2006). However, many brain disorders have important features in common. Although mental disorders account for two-thirds of the total cost of brain disorders (Andlinsobocki et al., 2005) they only receive one-third of the total investment in brain research. The proportion spent on mental disorders is even less when public investment (especially investment by charities) is considered alone. A possible explanation is that mental disorders have long been stigmatized and hence ‘invisible’, receiving little acknowledgement from healthcare providers and society in general (WHO, 2001b). Moreover, those working in the field of mental disorders have had difficulty organizing patients and special interest groups to inform policymakers and public funders of the importance of increasing understanding of the field. The majority of the world’s countries still lack data to support advocacy for mental health (WHO, 2001b), which could further explain the neglect of mental disorders on the public agenda. Indeed, many government agencies award research grants by selected themes (Editorial, 2004) and are influenced by lobbying forces. In the heterogeneous field of brain research, there has so far been little coordination of research efforts. Cancer is an example of a research field where successful coordination has been achieved. This has resulted in it receiving substantially more funds than brain research.

The industry sector is profit-driven and investments are therefore usually made where the expected profit is highest, i.e. where the cost of developing a new drug will give an anticipated profit (Vallance, 2001). Brain research is a field offering tremendous commercial opportunities, due to its high prevalence, chronicity and cost to the individual and to society [Invest in Sweden Agency (ISA), 2004].

Funding distribution by funding agencies

The results from the public funding survey on country-specific funding show large disparities between countries. Governments set their spending priorities according to tradition, political will, public influence, etc. According to Saraceno & Saxena (2004), in middle-income countries, mental health research has been constrained by such factors as resources, low research capacity and an unfavourable research environment (Saraceno & Saxena, 2004). In Eastern Europe, there has been a deterioration in health and social services since the collapse of Communism (Vlassov, 2005). Governments need strong public support if they are to invest in research, but this support is not present (European Commission, 2005b). Middle-income countries, especially, show low local support for research (Morris et al., 2002), which further explains the low public research investments in Eastern European countries (with exceptions such as Hungary).

Public attitude is also critical for charities. Charities are usually dependent on private donations for their work, and on private personal involvement (European Commission, 2005b). How much the public contributes to charities is, in turn, dependent on national traditions of donating. The strength and size of a charity is also partly influenced by how well organized the charitable sector is. As many charities focus on one specific disorder, there is a lack of charitable effort in the more general field of brain disorders (with exceptions such as the Brain Fund in Sweden), compared to the cancer field. Cooperation between funding agencies has been scarce, and it has been hard to find any coherence or efforts to reach a higher common goal (by lobbying or through better coordination). A well-organized charity sector has higher credibility among the public, encourages more charities to develop and promotes increased collaboration with other organizations, so that investments can be enlarged (European Commission, 2005b). Increased collaboration benefits all.

The largest charitable sector (in number and in spending) is in the UK. It is influential and well-organized through the government’s Charity Commission. All charities in the UK are registered by the Charity Commission, from which information about them (such as contact details, mission and annual reports) can easily be obtained (Charity Commission, 2006). There is also a tradition of collaboration between charities and government entities in the UK; this has made the charity sector more powerful in setting the national research agenda (European Commission, 2005b). One effect of collaboration is that there is a combined drive to map all mental health research funding from government agencies and charities, with the aim of improving knowledge about the funding situation and inspiring further collaboration (Mental Health Research Funders’ Group, 2005).

The large disparity in charity funding between European countries can partly be explained by national differences in laws and tax regulations that directly affect charities. Laws which limit or encourage charitable organizations include regulations affecting state approval for establishing a charity, requirements on starting capital, permitted purposes of the charity and regulations associated with the economic activity allowed (European Commission, 2005b). Tax regulations affect charities twice over, by affecting the incentives for people to donate and by relieving the charity of tax obligations. In the first case, some countries have tax deductions for private and/or corporate donors, which increase the incentives to donate. In the second, in many countries charities are exempt from taxes such as gift tax, inheritance tax and investment income tax, which makes their work more profitable and easier to manage. Many countries also exempt tax on public-benefit trading income and some even exempt tax on nonpublic-benefit trading income up to a certain threshold (European Commission, 2005b). The countries with more favourable laws for charities, such as the UK and the Netherlands (European Commission, 2005b), have reported high spending and numerous charities in the public funding survey. Many EU accession countries do not have as favourable incentives for charities (European Commission, 2005b), which could further explain the low charitable contribution reported in these countries.

While industry contributes 54% of total R&D spending in Europe, it contributes 79% of brain research funding. The goals of the Lisbon Strategy state that industry should contribute one-third of R&D investments and that the public should contribute 1% of GDP for research. In most fields, it is industry investments that are lagging behind, but the present study shows that for brain research it is public spending that must be increased proportionally more than industry spending. The key message of the Lisbon Strategy is that European research should be enhanced and brought up to an internationally comparable level. Today, however, insufficient research funding and a disorganized European research market are two of the largest obstacles to European brain research regaining its competitive edge globally (Sautter et al., 2003). Part of the problem can be solved by increasing public research funds.

The results of the present study indicate that there are differences in the amount of funding of disorder-specific research provided by the public and industry sectors. For example, industry has not invested in any research on TBI, most probably due to the limited number of drugs used specifically for the treatment of TBI, so the total research burden of TBI rests on the public. For brain tumour, in contrast, the division is more even, due to the large public interest in investing in this area. When setting its priorities for future research funding, it is
important that the public sector takes into account where both the gaps in funding and the largest health needs are (Institute of Medicine, 1998). The present results indicate that, taking public spending as a percentage of costs, brain tumour and TBI are the most highly funded brain disorders at 0.5% and 0.4%, respectively. The least funded brain disorders are mental disorders and migraine, which together receive less than 0.1% of the costs.

Growing gap between Europe and the US

Although the prevalence of brain disorders is similar in the US (National Institute of Neurological Disorders and Stroke, 2006) and Europe (Andlín-Sobocki et al., 2005), the results of the present study show that European government funding is only 12% of the spending of NIH. European public funding is also low compared to US funding of other fields of research.

The charity sector is much smaller in Europe than in the US (European Commission, 2005b). Part of the explanation for this is that Europe comprises many different countries with their own traditions, laws and regulations. Generally, tax exemptions on donations and the activities of charities are limited to the home country, which has led to difficulties with cross-border donations (European Commission, 2005b). In addition to low mobility of research capital, there is a low mobility of researchers (especially professors) within Europe (Dillon, 2001; European Commission, 2005b). As the extended academic market for capital and researchers is open within the US, this gives the US a significant competitive advantage (Editorial, 2004; European Commission, 2005b). The US also attracts many European scientists because research funding is better in the US (Edwards & Bell, 1994; Moore, 2000). This leads to a shortage of highly competent scientists in Europe, which has a negative effect on growth in the European research sector (Moore, 2000; Dillon, 2001).

As shown in the present study, both government and charity sectors are stronger in the US than in Europe. The US has a long tradition of private donations, not only to charities investing in medical research (European Commission, 2005b; Philipson, 2005). There has also been successful political lobbying by scientists in the US and this has influenced American public science policy (Moore, 2000; Simons, 2001). For decades, the US government has acknowledged the importance of R&D and, hence, has invested a considerable amount of resources in it. It has also made the investment climate favourable to industry. The US has long been the world leader in R&D and has dominated the published literature, where English has become the dominant language. A study by Fassoulaki et al. (2001) has shown that the impact factor (the number of citations of a scientific journal divided by the number of articles published) of published material in Europe is important for attracting further funding. As most journals are in English, many European countries are disadvantaged by not being able to conduct and publish research in their own language. These countries also have problems in attracting foreign scientists (Dillon, 2001). All these factors have probably had a negative effect on the advancement of European brain research.

Benefits of brain research investment

Publicly funded research can generate various types of benefits. Basic research can potentially lead to an increasing stock of useful knowledge, training of skilled graduates, creating new scientific instrumentation and methodologies, forming networks and stimulating social interaction, increasing the capacity for scientific and technological problem-solving and creating new companies (Salter & Martin, 2001). These all contribute to economic growth. Of these categories, health research should primarily affect the patients’ lives by increasing knowledge and by the creation of new instruments and methods. Studies have shown that health research has led directly to cost savings and increases in healthy lifespan (Buxton et al., 2004; Johnston et al., 2006), mainly through more effective treatments (Buxton et al., 2004).

In the present study, we provided examples of the benefits of medical innovation, and suggested that substantial benefits have been gained in several major brain disorders over recent decades. New drugs have delayed progression into severe states for patients affected by brain disorders, or eased the symptoms and thereby reduced the burden on society while increasing the patients’ QoL. Even small effects of relief or delayed progression may provide large benefits to patients. Hence, there is a substantial potential for future medical innovations to provide even larger benefits than the drugs that are currently available. Our assessment of future benefits from further investments in brain research indicates that these are worthwhile, based on society’s WTP for further health gains. Even at low levels of WTP for health gains, research was found to be highly cost-effective. By studying the development pipelines of medical innovations, we already note that drugs targeting diseases of the CNS account for most of these. However, in the public sector, brain research still seems to be under-prioritized.

Conclusions

Spending on brain research in Europe, particularly public spending, is low compared to other fields of research, such as cancer, and it is particularly low compared to the US. Increased public investment in brain research in Europe may be highly cost-effective and bring great benefits. The EC prioritization of brain research in the Seventh Framework Programme of Research is supported by the present data. Each European nation should follow the example of the EC and make brain research one of its research priorities for the years to come. It is important that both basic and clinical research receive adequate funding. Basic research is responsible for the most fundamental breakthroughs and often leads to subsequent paradigm shifts in drug development and patient treatment. Clinical research may direct basic research towards disease-related mechanisms and is instrumental in translating findings of basic research into new products and treatments.

Using the same methodologies as in the present study, future studies could be undertaken in each European country to assess more precisely the spending on brain research. To facilitate more accurate future studies, industry and public funding bodies should group funding for ‘brain research’ together, including stroke, brain tumour, developmental disorders, mental retardation, brain trauma and brain infections. This would enable future studies to establish the necessary priorities for investments in brain research.

Acknowledgement

This work was supported by a Specific Support Action grant (number 013043) from the European Commission under the Sixth Framework Programme.

Abbreviations

CMR, Centre for Medicines Research; CNS, central nervous system; CPL, comparative price level; CVD, cardiovascular diseases; DALY, disability-adjusted life years; EBC, European Brain Council; EC, European Commission; EU, European Union; ECRM, European Cancer Research Managers forum; EFPIA, European Federation of Pharmaceutical Industries and Associations; EQ-5D, EuroQol in five dimensions; GAD, generalized anxiety disorder; GDP, gross domestic product; MS, multiple sclerosis; NCE, new chemical entity; NIH, National Institutes of Health; OECD, Organization for Economic Co-operation and Development; PD, Parkinson’s disease; QALY, quality-adjusted life years; QoL, quality of life; R&D, research and development; TBI, traumatic brain injury; WHO, World Health Organization; WTP, willingness to pay.
List of contributors

Project committee

Patrik Sobocki, Karolinska Institutet, Medical Management Centre and Stockholm Health Economics, Stockholm, Sweden; Ingrid Lekander, Stockholm Health Economics, Stockholm, Sweden; Sophie /Berwick, Stockholm Health Economics, Stockholm, Sweden; Jes Olesen, Department of Neurology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark; Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden

Other contributors (in alphabetic order)

Andrew Aicken, Department of Health, Social Services and Public Safety, Northern Ireland, UK; Yvonne Allen, British Neuroscience Association, UK; Christer Allgulander, Karolinska Institutet, Sweden; Carina Alm, Nasjonalforeningen Demensforbundet, Norway; Rafael de Andrés Medina, Instituto de Salud Carlos III—Ministerio de Sanidad y Consumo, Spain; Lennart Angere, Lund University, Sweden; Joaquin Arenas, Instituto de Salud Carlos III—Ministerio de Sanidad y Consumo, Spain; Antti Arja, Finnish Cultural Foundation, Finland; Gerrit van Ark, Netherlands Organisation for Health Research and Development, Netherlands; Christine Auberton, France Alzheimer et Maladies Apparentées, France; Gilles Aumont, National Institute of Agriculture Research, France; Julio Barbas, Ministerio de Educación y Ciencia, Spain; Claudia Bazzoni, Wales Office of R&D, UK; Carlos Belmonte, Consejo Superior de Investigaciones Científicas, Spain; Nadine Belzic, Institut National de la Santé et de la Recherche Médicale, France; Silvia Benes, Wiener Wissenschafts-, Forschungs- und Technologiefonds, Austria; Einar Berdal, Danish MS Society, Denmark; Henk Berendse, Dutch Neurofederation, Netherlands; Alexandre Bisdorff, Hôpital de Ville, Luxembourg; Daniela Bjørne, Stroke-Riksforbundet, Norway; Ulf Björnstig, Cancer och Trafikskadefonden, Sweden; Dag Hervieu, Va˚rdalstiftelsen, Sweden; Berit Druse, Barncancerfonden, Sweden; Seth Eckhouse, European Cancer Research Managers Forum, UK; Tracy Egan, Irish Heart Foundation, Ireland; Edvard Ehler, Nemocnice Pardubice, Czech Republic; Britt-Marie Eklund, Swedish Governmental Agency for Innovation Systems, Sweden; Charlotte Enderlein, Radiumhemmets Forskningsfond, Sweden; Hillevi Engrant, Hjärnfonden, Sweden; Otilia Fernández, Gerente Fomentación Mutua Madrileña, Spain; Carla Finocchiaro, CF Consulting, Italy; Dennis Fisher, MS Research and Relief Fund, UK; Colette Fitzpatrick, Irish Institute of Clinical Neuroscience, Ireland; Marios Florou, Cyprus Institute of Neurology and Genetics, Cyprus; Lars Forsgren, Umeå University Hospital, Sweden; Magne Wang Fredriksen, Norges Parkinsonforbund, Norway; Sten Fredriksen, Karolinska University Hospital, Sweden; Joseph Gaut, Centre de Recherche Publique-Santé, Luxembourg; Jes Gerlach, Danish Mental Health Fund, Denmark; Nils Gilhus, Haukeland University Hospital, Norway; Antonio Gil-Nagel, Hospital Ruber Internacional, Spain; Zsuzsanna Gilyéni, Hungarian Scientific Research Fund, Hungary; Frank Glod, Fonds National de la Recherche, Luxembourg; Astrid Golla, Deutsche Forschungsgemeinschaft, Germany; Thomas Griesbacher, Austrian Pharmacological Society, Austria; Wolfgang Grisold, Kaiser-Franz-Josef Spital, Austria; Sverrir Gudmundsson, University of Iceland Research Fund, Iceland; Hans Gudmundsson, Icelandic Science Fund, Iceland; Solange Guenez, Fondation de France, France; Ulf Guttormsson, Systembolagens Råd för Alkoholforskning, Sweden; Werner Hacke, Universitätssklinikum, Germany; Margus Harak, Estonian Ministry of Education and Research, Estonia; Henrike Hartmann, Volkswagen Stiftung, Germany; Rob Heinsbroek, Netherlands Organisation for Health Research and Development, Netherlands; Zsuzsa Herczeg, Ministry of Health, Hungary; Dag Hervieu, Vårdalstiftelsen, Sweden; Christian Hess, Inselspital, Switzerland; Benno Hinnekint, Fonds voor Wetenschappelijk Onderzoek—Vlaanderen, Belgium; Stanislav Hlavac, Research and Development Agency, Slovakia; Sandra Hogan, Aware, Ireland; Ruzena Holadova, Grant Agency of the Czech Republic, Czech Republic; Isabella von Holstein, Epilepsy Research Foundation, UK; Peter Hoogendoorn, Parkinson Patients Vereniging, Netherlands; Brian Howard, Mental Health Ireland, Ireland; Sabine Jansen, Deutsche Alzheimer Gesellschaft, Germany; Cristina Januário, Portuguese Neurological Society, Portugal; Roos de Jonge, Princes Beatrix Fonds, Netherlands; Theresia Junker, Swiss Heart Foundation, Switzerland; Linus Jönsson, European Health Economics, Sweden/UK; Maria Karlsson, Stiftelsen Solstickan, Sweden; Lindsay Kinnaird, Alzheimer Scotland—Action on Dementia, UK; Peter van’t Klooster, Netherlands Institute for Brain Research and Netherlands Ophthalmic Research Institute, Netherlands;

Michael Clark, Department of Health, UK; Anne Cody, Health Research Board, Ireland; Peter Coleman, Stroke Association, UK; Peter Craig, Scottish Executive Health Department, UK; Emer Cunningham, Higher Education Authority, Ireland; Lynne Davies, Cancer Research UK, UK; Richard Dodel, Friedrich-Wilhelms-Universität, Germany; Bjørn Druze, Barncancerfonden, Sweden; Edvard Ehler, Nemocnice Pardubice, Czech Republic; Britt-Marie Eklund, Swedish Governmental Agency for Innovation Systems, Sweden; Charlotte Enderlein, Radiumhemmets Forskningsfond, Sweden; Hillevi Engrant, Hjärnfonden, Sweden; Otilia Fernández, Gerente Fomentación Mutua Madrileña, Spain; Carla Finocchiaro, CF Consulting, Italy; Dennis Fisher, MS Research and Relief Fund, UK; Colette Fitzpatrick, Irish Institute of Clinical Neuroscience, Ireland; Marios Florou, Cyprus Institute of Neurology and Genetics, Cyprus; Lars Forsgren, Umeå University Hospital, Sweden; Magne Wang Fredriksen, Norges Parkinsonforbund, Norway; Sten Fredriksen, Karolinska University Hospital, Sweden; Joseph Gaut, Centre de Recherche Publique-Santé, Luxembourg; Jes Gerlach, Danish Mental Health Fund, Denmark; Nils Gilhus, Haukeland University Hospital, Norway; Antonio Gil-Nagel, Hospital Ruber Internacional, Spain; Zsuzsanna Gilyéni, Hungarian Scientific Research Fund, Hungary; Frank Glod, Fonds National de la Recherche, Luxembourg; Astrid Golla, Deutsche Forschungsgemeinschaft, Germany; Thomas Griesbacher, Austrian Pharmacological Society, Austria; Wolfgang Grisold, Kaiser-Franz-Josef Spital, Austria; Sverrir Gudmundsson, University of Iceland Research Fund, Iceland; Hans Gudmundsson, Icelandic Science Fund, Iceland; Solange Guenez, Fondation de France, France; Ulf Guttormsson, Systembolagens Råd för Alkoholforskning, Sweden; Werner Hacke, Universitätssklinikum, Germany; Margus Harak, Estonian Ministry of Education and Research, Estonia; Henrike Hartmann, Volkswagen Stiftung, Germany; Rob Heinsbroek, Netherlands Organisation for Health Research and Development, Netherlands; Zsuzsa Herczeg, Ministry of Health, Hungary; Dag Hervieu, Vårdalstiftelsen, Sweden; Christian Hess, Inselspital, Switzerland; Benno Hinnekint, Fonds voor Wetenschappelijk Onderzoek—Vlaanderen, Belgium; Stanislav Hlavac, Research and Development Agency, Slovakia; Sandra Hogan, Aware, Ireland; Ruzena Holadova, Grant Agency of the Czech Republic, Czech Republic; Isabella von Holstein, Epilepsy Research Foundation, UK; Peter Hoogendoorn, Parkinson Patients Vereniging, Netherlands; Brian Howard, Mental Health Ireland, Ireland; Sabine Jansen, Deutsche Alzheimer Gesellschaft, Germany; Cristina Januário, Portuguese Neurological Society, Portugal; Roos de Jonge, Princes Beatrix Fonds, Netherlands; Theresia Junker, Swiss Heart Foundation, Switzerland; Linus Jönsson, European Health Economics, Sweden/UK; Maria Karlsson, Stiftelsen Solstickan, Sweden; Lindsay Kinnaird, Alzheimer Scotland—Action on Dementia, UK; Peter van’t Klooster, Netherlands Institute for Brain Research and Netherlands Ophthalmic Research Institute, Netherlands;

© The Authors (2006). Journal Compilation © Federation of European Neuroscience Societies and Blackwell Publishing Ltd

European Journal of Neuroscience, 1–24
Bernhard Knappe, Wilhelm-Sander-Stiftung, Germany;
Gisela Kobelt, European Health Economics, France;
Annemieke van der Kooij, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Netherlands;
Peter Kropp, Deutsche Migräne- und Kopfschmerzgesellschaft, Germany;
René Kruijff, Stichting Internationaal Parkinson Fonds, Netherlands;
Dott Cinzia Kutschera, Ministero della Salute, Italy;
Gunnilla Källberg, Cancerfonden, Sweden;
Janika Körv, University of Tartu, Estonia;
Lars Narve Larsen, Melzerfondet, Norway;
Beatrice Lawal, Fonds zur Förderung der wissenschaftlichen Forschung, Austria;
Claire Lazare, British Heart Foundation, UK;
Cor van Leeuwen, Netherlands Institute for Brain Research and Netherlands Ophthalmic Research Institute, Netherlands;
Dr. Lenz, Association Luxembourgeoise de la Maladie de Parkinson, Luxembourg;
Susanna Lindvall, Parkinsonfonden, Sweden;
Sharyn Long, MS Society of Ireland, Ireland;
Gisela Kobelt, Fondation Luxembourgeoise contre le Cancer, Luxembourg;
Susanna Lindvall, Parkinsonfonden, Sweden;
Janika Körv, University of Tartu, Estonia;
Lars Narve Larsen, Melzerfondet, Norway;
Beatrice Lawal, Fonds zur Förderung der wissenschaftlichen Forschung, Austria;
Gunnilla Källberg, Cancerfonden, Sweden;
Dott Cinzia Kutschera, Ministero della Salute, Italy;
Rene´ Kruijff, Stichting Internationaal Parkinson Fonds, Netherlands;
Beatrice Lawal, Fonds zur Förderung der wissenschaftlichen Forschung, Austria;
Claire Lazare, British Heart Foundation, UK;
Cor van Leeuwen, Netherlands Institute for Brain Research and Netherlands Ophthalmic Research Institute, Netherlands;
Dr. Lenz, Association Luxembourgeoise de la Maladie de Parkinson, Luxembourg;
Susanna Lindvall, Parkinsonfonden, Sweden;
Sharyn Long, MS Society of Ireland, Ireland;
Gabriela Lopes da Silva, Fundação para a Ciência e a Tecnologia, Portugal;
Jose Lopez Lima, Liga Portuguesa Contra a Epilepsia, Portugal;
Monica di Luca, University of Milan, Italy;
Mia Lundström, Neurologiskt Handikappades Riksförbund-fonden, Sweden;
Ige Maalman, Estonian Science Foundation, Estonia;
Michael Madeja, Hertie Foundation, Germany;
Birgitta Martenson, Association Alzheimer Suisse, Switzerland;
Mark Matfield, Association for International Cancer Research, UK;
Chris Messis, Mental Health Commission and Cyprus Neurological Society, Cyprus;
Tracy Moloney, Science Foundation Ireland, Ireland;
Lucia Monaco, Telethon, Italy;
Tina Mose, Dansk Epilepsiforening, Denmark;
Peter Murphy, Migraine Association of Ireland, Ireland;
Raymond Murphy, Tallaght Hospital, Ireland;
Susann Mörrck, Neurologistiftelser, Finland;
Yessra Nawaz, British Pharmaceutical Society, UK;
Mari Nes, Research Council of Norway, Norway;
Eila Niemi, Finnish MS Society, Finland;
Riekje van Nies, Hersenstichting Nederland, Netherlands;
Marga Nijenhuis, Stichting MS Research, Netherlands;
Birgitta Nyström, Umeå University, Sweden;
Michael Oddy, Brain Injury Rehabilitation Trust, UK;
Anita Oldhoff, Alzheimer Nederland, Netherlands;
Rolf-Erik Olsson, Insamlingsstiftelsen för Alzheimer- och Demensforskning, Sweden;
Grzegorz Opala, Polish Neurological Society, Poland;
Lars Oredal, Uppsala University, Sweden;
Anastasios Orlofas, Greek MS Society, Greece;
Raimo Pakkanen, Finnish Funding Agency for Technology and Innovation, Finland;
Olaf Paulson, Alzheimerforeningene, Denmark;
José Pereira Monteiro, Hospital Santo António, Portugal;
Sarah Perkins, Medical Research Council, UK;
Christian Pilebæk Hansen, Dansk Epilepsi Selskab, Denmark;
Paavo Pokk, Estonian Society of Pharmacology, Estonia;
Dominique Pouilain, Institut National de la Santé et de la Recherche Médicale, France;
Marie-Paule Prost-Heinisch, Fondation Luxembourgeoise contre le Cancer, Luxembourg;
Fernando Ramôa Ribeiro, Fundação para a Ciência e a Tecnologia, Portugal;
Lorenz Ramseyer, Centre for Technology and Innovation, Switzerland;
Margaret Rawnslay, British Epilepsy Association, UK;
Francesca Reina, CF Consulting, Italy;
Ben Roelands, Nationaal Fonds Geestelijke Volksgezondheid, Netherlands;
Bjarne Rosted, Norwegian Cancer Society, Norway;
Ingegerd Runesson, Vetenskapsrådet, Sweden;
Anita Rupprecht, Government of Styria, Austria;
Iain Ryrie, Mental Health Foundation, UK;
Terje Sagvolden, Norwegian Neuroscience Society, Norway;
Anne Sanderson, Wellcome Trust, UK;
Jürgen Sautter, European Commission, Belgium;
Birgitta Schannong Schlytern, Hjärnfonden, Sweden;
Jean Schoenen, Centre Hospitalier Regional de la Citadelle, Belgium;
Patricia Servais, Belgian Federation Against Cancer, Belgium;
Werner Sieghart, Medical University of Vienna, Austria;
Wilma Simoleit, Deutsche Krebshilfe, Germany;
Eva Siracka, League Against Cancer Slovakia, Slovakia;
Anders Sjölund, Stiftelsen för Strategisk Forsknings, Sweden;
Elaine Snell, Snell Communications, UK;
Per Soelberg Sörensen, Copenhagen University Hospital, Denmark;
Hilkka Soininen, University of Kuopio, Finland;
Magda Solti, National Office of Research and Technology, Hungary;
Lennart Sparell, Cancer-och allergifonden, Sweden;
Günther Sperk, Bundesministerium für Bildung, Wissenschaft und Kultur, Austria;
Helle Birgitte Strøm, Danish Medical Research Council, Denmark;
Sigurlaug Sveinbjörnsdottir, University Hospital, Iceland;
Josef Syka, Czech Science Foundation, Czech Republic;
Eva Tallkvist, Sigrid Juselius Foundation, Finland;
Christianne Tihon, Ligue Belge de la Scclérose en Plaques, Belgium;
Mika Tirronen, Academy of Finland, Finland;
Thomas Truelsen, Copenhagen University Hospital, Denmark;
Fanny Valleix, Agence Nationale de la Recherche–Institut National de la Santé et de la Recherche Médicale, France;
Laszlo Vecsei, University of Szeged, Hungary;
Vicente Vega, Hjärt-Lungfonden, Sweden;
Hedwig Verhaegen, Flemish League against Cancer, Belgium;
Henk Vermaat, Netherlands Heart Foundation, Netherlands;
Manfred Westphal, University of Hamburg, Germany;
Nils Wilking, Karolinska Institutet, Sweden;
David Vodusek, University Medical Centre, Slovenia;
Astrid Zuurbier, Dutch Cancer Society, Netherlands.
European Journal of Neuroscience

Contents

Research Reports

2691 Resource allocation to brain research in Europe (RABRE)
P. Sobocki, I. Lekander, S. Berwick, J. Olesen and B. Jönsson

2694 Calcium–calmodulin-dependent protein kinase II phosphorylation modulates PSD-95 binding to NMDA receptorsF. Gardoni, F. Polli, F. Cattabeni and M. Di Luca


2721 The cytokine/neurotrophin axis in peripheral axon outgrowthG. Gölo, L. Uhlmann, D. Lüdecke, N. Markgraf, R. Nitsch and S. Hendrix

2731 Hypothalamic proopiomelanocortin (POMC) neurons have a cholinergic phenotypeB. Meister, B. Gömüç, E. Suarez, Y. Ishii, K. Dürr and L. Gillberg

2741 N-ethylmaleimide increases release probability at GABAergic synapses in layer I of the mouse visual cortexK. Kirmse and S. Kirischuk

2758 Repair process of fetal brain after 5-azacytidine-induced damageM. Ueno, K.-i. Katayama, H. Yamauchi, A. Yasoshima, H. Nakayama and K. Doi

2769 The serotonergic inhibition of slowly bursting cells in the intergeniculate leaflet of the ratT. Blaas, E. Stoep, S. Raasen, P. Pevat and M. R. Lewandrowski

2781 Enzymes and norepinephrine empty convergent mechanisms to depress excitatory synaptic transmission in the rat nucleus accumbens in vitroS. B. Kombian, K. V. V. Ananthakrishnini and J. G. Edalati

2799 Bidirectional regulation of dopamine D2 and neurotensin NT51 receptors in dopamine neuronsC. Jonghe, P.-L. Lamalle, M. Okano, K. Kobayashi and L.-E. Trudeau

2801 Topographical organization of pathways from somatosensory cortex through the pontine nuclei to tactile regions of the rat cerebellar hemispheresT. E. Leergaard, S. Lillehaug, E. W. Schiffer, J. M. Bower and J. G. Blaaue

2813 Difference in organization of corticostriatal and thalamostriatal synapses between patch and matrix compartments of rat neocortexF. Fayyama, T. Urnai, K. Nakamura, S. Nomura and T. Kaneko

2825 Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orphan 1 receptor in the ratP. R. Holand, S. Akerman and P. J. Goodbody

Cover Illustrations

Map transformations in the rat somatosensory system. Tactile information from the body surface is represented in a somatotopic map in the primary somatosensory cortex (left panel). This essentially 2-D cortical map is transformed into a more complex 3-D map in the pontine nuclei (middle), in which somatosensory columns are largely preserved among adjacent terminal fields. In the granule cell layer of the cerebellar hemispheres (right), tactile representations are organized in a more complex and disrupted map, referred to as a fractional map, as here shown in folium crus IIa and the paramedian lobule. Body parts are color coded (red, upper lip; purple, whisker; green, trunk; yellow, forelimb; green, hindlimb). For details see T.B. Leergaard et al. (pp. 2801–2812).

EJN is covered in Biological Abstracts, Current Awareness in Biological Science, BIOSIS/Current Awareness in Biological Sciences, Current Contents/Life Science, EMBASE, Reference Update Deluxe Edition, Research Alert, Science Citation Index, Scopus, Social Science Citation Index

Typeset in India by Scientific Publishing Services (P) Ltd
Printed in Singapore by KHE Printing Co Pte Ltd
ISSN: 0953-816X (Print)
ISSN: 1460-9568 (Online)

For submission instructions, subscription and all other information visit: www.blackwellpublishing.com/journals/ejn

This journal is available online at Blackwell Synergy. Visit www.blackwell-synergy.com to search the articles and register for table of contents e-mail alerts.